期刊文献+

HPLC-荧光法测定醛糖还原酶的活性 被引量:1

Analysis of aldose reductase enzymatic activity by HPLC with fluorescence detector
在线阅读 下载PDF
导出
摘要 目的建立一种基于NADP+衍生物荧光的高灵敏度的体外测定醛糖还原酶(aldose reductase,AR)活性的HPLC方法。方法从大鼠的肾脏中分离纯化AR,以DL-甘油醛为底物,加入NADPH启动酶促反应。以C18柱分离NADP+衍生物,流动相为乙腈∶水(75∶25),流速1.0 ml.min-1,柱温25℃,荧光检测激发波长370 nm,发射波长465 nm。测定NADP+衍生物的稳定性以及NADPH、DL-甘油醛、pH、温度对AR活性的影响。结果 NADP+衍生物稳定性好,保留时间为(1.4±0.01)min,附近无干扰峰,其浓度与荧光强度线性关系良好(r=0.9994),最低检测限为25 pmol。日内和日间精密度均小于10%。结论本方法操作简单、灵敏度高、特异性强,可用于体外AR的活性的测定。 Aim To establish a sensitive HPLC method for the determination of aldose reductase(AR) activity,based on the HPLC analysis of NADP+ derivative fluorescence formed by AR.Methods AR was isolated and purified from rat kidney.The mobile phase was acetonitrile-water(75 ∶ 25) delivered at a flow rate of 1.0 ml.min-1 by isocratic reversed-phase elution on C18 column.The temperature was controlled at 25 ℃ and the fluorescence of NADP+ derivative was monitored at 370 nm /465 nm.The effect of NADPH,DL-glyceraldehyde,pH,and temperature on AR activities was studied.Results The NADP+ derivative was stable,whose retention time was(1.4 ± 0.01) min with no interference peaks.A good linearity was observed(r = 0.9994) with the detection limit at 25 pmol.Both the inter-day and intraday precision was less than 10%.Conclusion The method is simple,sensitive and credible and can be used for the determination of AR activities.
出处 《中国药理学通报》 CAS CSCD 北大核心 2012年第10期1472-1475,共4页 Chinese Pharmacological Bulletin
基金 澳门大学研究基金[No MYRG161(Y2-L2)-ICMS11-CXP]
关键词 醛糖还原酶 HPLC NADP+衍生物 荧光 大鼠 肾脏 aldose reductase HPLC NADP + derivative fluorescence rats kidney
作者简介 陈修平(1977-),男,博士,助理教授,研究方向:药理学,Tel:0853-83974873,E—mml:xpchen@umac.mo; 石京山(1959-),男,博士,教授,研究方向:药理学,E-mNl:shijs@zmc.edu.cn
  • 相关文献

参考文献12

  • 1Ramana K V, Srivastava S K. Aldose reductase : a novel therapeutic target for inflammatory pathologies[J]. Int J Biochem Cell Bill, 2010, 42(1):17 -20.
  • 2Reddy A B, Ramana K V. Aldose reductase inhibition: emerging drug target for the treatment of cardiovascular complications [ J ]. Recent Pat Cardiovasc Drug Discov, 2010 ,5 (1) :25 -32.
  • 3Ramirez M A, Borja N L. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic nenropathy[J]. Pharmacotherapy, 2008,28 (5) :646 - 55.
  • 4Gabbay K H, Kinoshita J H. Methods in enzymology [ M ]. New York : New York Academic Press, 1975 : 159.
  • 5Dufrane S P, Malaisse W J, Sener A. A micromethod for the assay of aldose reductase, its application to pancreatic islets [ J ]. Biochem Med, 1984,32( 1 ) :99 - 105.
  • 6Maddox I S. A radiolabeled assay for aldose reductase[J]. Can J Biochem, 1974 , 52(9) :807 -9.
  • 7Mcdonald G, Clark A F, Flynn T G. Quantitation by radioimmunoassay of aldose reductase ( ALR2 ) in normal and diabetic rats [J]. Prog Clin Biol Res, 1987, 232:367 -75.
  • 8Yishimura C, Furue M, Ito T, et al. Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reduetase[J]. Biochem Pharmacol, 1993,46(1): 21 -8.
  • 9Chakrabarti S, Sima A A, Nakajima T, et al. Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve [J]. Diabetologia, 1987, 30 (4): 244 -51.
  • 10Sato S. Rat kidney aldose reductase and aldehyde reductase and polyol production in rat kidney [ J ]. Am J Physiol, 1992,263 (5 Pt 2 ): F799 - 805.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部